Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of MGC018 (Anti-B7-H3 Antibody Drug Conjugate) Alone and in Combination With MGA012 (Anti-PD-1 Antibody) in Patients With Advanced Solid Tumors

NCT03729596 is registered in ClinicalTrials.gov with MacroGenics as lead sponsor.

NCT NCT03729596
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03729596 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of MGC018 (Anti-B7-H3 Antibody Drug Conjugate) Alone and in Combination With MGA012 (Anti-PD-1 Antibody) in Patients With Advanced Solid Tumors
Lead sponsor
MacroGenics
Phase
Phase 1/2
Overall status
Terminated
Start date
November 21, 2018
Completion date
March 18, 2023
Enrollment
143 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, adult, melanoma, metastatic castrate resistant prostate cancer, non small cell lung cancer, squamous cell carcinoma of head and neck, triple negative breast cancer